<DOC>
	<DOC>NCT01434498</DOC>
	<brief_summary>This is a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin; GS-5885, GS-9451 and Tegobuvir; GS-5885, GS-9451 and Ribavirin in Interferon Ineligible or Intolerant Subjects with Chronic Genotype 1a or 1b HCV Infection.</brief_summary>
	<brief_title>GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>Adult subjects 18 and older with chronic HCV infection Liver biopsy results (performed no more than 3 years prior to Screening) indicating the absence of cirrhosis Monoinfection with HCV genotype 1a or 1b Interferon ineligible or intolerant Body mass index (BMI) between 18 and 40 kg/m2 Use of highly effective contraception methods if female of childbearing potential or sexually active male Screening laboratory values within defined thresholds Has not been exposed to any investigational drug or device within 30 days of the Screening visit Able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments Prior treatment of HCV with any directacting antiviral (whether approved or experimental) Decompensated liver disease or cirrhosis Coinfection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or another HCV genotype History of difficulty with blood collection and/or poor venous access Pregnant or nursing female or male with pregnant female partner Chronic liver disease of a nonHCV etiology Suspicion of hepatocellular carcinoma Clinicallyrelevant drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Rapid Virologic Response</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>Tegobuvir</keyword>
	<keyword>Treatment na√Øve</keyword>
	<keyword>HCV RNA</keyword>
	<keyword>Polymerase inhibitor</keyword>
	<keyword>Protease inhibitor</keyword>
	<keyword>Interferon intolerant</keyword>
	<keyword>Interferon ineligible</keyword>
	<keyword>GS-9190</keyword>
	<keyword>GS-9451</keyword>
	<keyword>GS-5885</keyword>
</DOC>